Sleep Health Research Feasibility Review
A Case Study in Regulatory Readiness, Governance Integrity, and Cross-Border Research Risk
Prepared by: Dr. Noha M Gibreel, Dr. Yara Ashour and Dr. Abdallah Jlambo
Reviewed & edited by: Dr. Suliman E Ahmed
Date: 31 January 2026
Scope of Engagement
Dr. Suliman Advisory Group (DSAG) was engaged to conduct an independent feasibility and risk assessment for a proposed cross-border sleep health research initiative. The engagement focused on evaluating regulatory readiness, governance integrity, and enterprise-level risk prior to any operational collaboration, consistent with DSAG’s risk-aware advisory model and alignment with internationally recognized research governance standards.
Assessment Focus
The review assessed whether the proposed initiative demonstrated the institutional, ethical, and operational foundations required for compliant execution of global health research. DSAG applied a preventive, standards-aligned evaluation lens, emphasizing early identification of regulatory, funding, data-governance, and reputational risk, rather than post-hoc remediation.
This approach reflects established best practices in international research oversight, including principles embedded within globally accepted ethical, regulatory, and data-protection frameworks governing human subjects research and cross-border data activity.
Key Risk Domain Findings
Regulatory and Ethical Readiness
While the research concept demonstrated scientific potential, no verifiable documentation of independent ethics committee or Institutional Review Board (IRB) approval was provided. In multi-jurisdictional research environments, the absence of confirmed ethical oversight represents a material compliance gap and limits defensibility under internationally accepted research standards.
DSAG assessment: Regulatory readiness was insufficient to support operational participation.
Operational and Financial Clarity
The proposed collaboration lacked a defined operational framework, including formal contracts, scope delineation, timelines, deliverables, and compensation mechanisms. This absence introduced uncertainty around accountability, funding alignment, and execution sustainability.
DSAG assessment: Operational ambiguity created avoidable execution and financial risk.
An infographic highlighting ICH-GCP core principles, ethical foundations, and global regulatory harmonization aligned with the Helsinki Principles.
Governance and Data Compliance
No formal data governance framework was presented to address data ownership, privacy safeguards, or cross-border transfer requirements. In the absence of documented controls, the initiative was exposed to heightened compliance risk under prevailing international data-protection and research governance regimes.
DSAG assessment: Governance and data-compliance structures were not fit for cross-border research activity.
Enterprise and Reputational Risk
Institutional legitimacy and legal incorporation of the proposing entity could not be independently verified. Proceeding without confirmation of institutional standing would have created unnecessary enterprise-level and reputational exposure for participating stakeholders.
DSAG assessment: Reputational risk exceeded acceptable thresholds for operational engagement.
Strategic Determination
Following cumulative evaluation across regulatory, governance, operational, and enterprise domains, DSAG determined that operational collaboration was not viable in the initiative’s current state. This determination reflected the overall risk profile and readiness gaps, rather than a judgment on scientific merit alone.
Conditions for Future Consideration
DSAG identified clear prerequisites required for reassessment of operational involvement, including:
- Verified IRB or independent ethics committee approval
- Confirmed legal incorporation and institutional affiliation
- Formal contractual frameworks defining scope, responsibilities, timelines, and compensation
- Documented data-governance and cross-border compliance protocols
Advisory Position
DSAG remains available to support the initiative in an advisory-only capacity, providing strategic guidance on regulatory readiness, ethical governance design, and compliance framework development until operational readiness can be independently demonstrated.
Strategic Insight
This case illustrates DSAG’s core advisory philosophy: scientific innovation achieves scale and credibility only when supported by verified governance, ethical oversight, and institutional accountability. Early-stage feasibility and risk discipline protects funding viability, regulatory standing, and long-term reputational integrity, enabling research initiatives to progress with confidence rather than corrective urgency.
Dr. Suliman E. Ahmed, M.D.
Founder and CEO, Dr. Suliman Advisory Group LLC
